• 011-26907444
  • raghava@iiitd.ac.in

Welcome to Peptide Card of AntiTbPdb

This page displays user query in tabular form.

CLLKKLLKK details
Primary information
ID antitb_1234,
Name24314557
N-Terminal modificationC(LLKK)2
C-Terminal ModificationCLLKKLLKK
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium smegmatis
In Vitro/ In vivoMycobacterium smegmatis (ATCC No. 14468)
Cell LineMIC = 62.5 mg/L
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityRat red blood cells (rRBCs)
In vivo ModelNA
Lethal DoseVery low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyMembrane-lytic mechanism
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1235,
Name24314557
N-Terminal modificationC(LLKK)2
C-Terminal ModificationCLLKKLLKK
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium smegmatis
In Vitro/ In vivoMycobacterium smegmatis resistant agianst rifampicin
Cell LineMIC = 62.5 mg/L
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityRat red blood cells (rRBCs)
In vivo ModelNA
Lethal DoseVery low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyMembrane-lytic mechanism
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1236,
Name24314557
N-Terminal modificationC(LLKK)2
C-Terminal ModificationCLLKKLLKK
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium bovis
In Vitro/ In vivoMycobacterium bovis BCG lux
Cell LineMIC = 250 mg/L
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityRat red blood cells (rRBCs)
In vivo ModelNA
Lethal DoseVery low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyMembrane-lytic mechanism
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1237,
Name24314557
N-Terminal modificationC(LLKK)2
C-Terminal ModificationCLLKKLLKK
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium tuberculosis
In Vitro/ In vivoMycobacterium tuberculosis H37Rv
Cell LineMIC > 500 mg/L
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityRat red blood cells (rRBCs)
In vivo ModelNA
Lethal DoseVery low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyMembrane-lytic mechanism
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1238,
Name24314557
N-Terminal modificationC(LLKK)2
C-Terminal ModificationCLLKKLLKK
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium tuberculosis
In Vitro/ In vivoMycobacterium tuberculosis CSU87 reistant to rifampicin, isoniazid, ethambutol, streptomycin and kanamycin
Cell LineMIC > 500 mg/L
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityRat red blood cells (rRBCs)
In vivo ModelNA
Lethal DoseVery low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyMembrane-lytic mechanism
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),